PMID- 24729492
OWN - NLM
STAT- MEDLINE
DCOM- 20170413
LR  - 20201209
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 59
IP  - 3
DP  - 2014 Aug 1
TI  - Lipid levels and changes in body fat distribution in treatment-naive, 
      HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the 
      ECHO and THRIVE trials.
PG  - 425-34
LID - 10.1093/cid/ciu234 [doi]
AB  - BACKGROUND: Pooled ECHO/THRIVE lipid and body fat data are presented from the 
      ECHO (Efficacy Comparison in Treatment-Naive, HIV-Infected Subjects of TMC278 and 
      Efavirenz) and THRIVE (TMC278 Against HIV, in a Once-Daily Regimen Versus 
      Efavirenz) trials. METHODS: We assessed the 96-week effects on lipids, adverse 
      events (AEs), and body fat distribution (dual-energy x-ray absorptiometry) of 
      rilpivirine (RPV) and EFV plus 2 nucleoside/nucleotide reverse transcriptase 
      inhibitors (N[t]RTIs) in treatment-naive adults infected with human 
      immunodeficiency virus type 1 (HIV-1). RESULTS: Rilpivirine produced minimal 
      changes in total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), 
      high-density lipoprotein cholesterol (HDL-C), and triglycerides. Compared with 
      RPV, EFV significantly (P < .001) increased lipid levels. Decreases in the 
      TC/HDL-C ratio were similar with RPV and EFV. Background N[t]RTI affected 
      RPV-induced lipid changes; all levels increased with zidovudine/lamivudine (3TC) 
      and abacavir/3TC (except triglycerides, which were unchanged). With 
      emtricitabine/tenofovir, levels of HDL-C were increased, TC and LDL-C were 
      unchanged, and triglycerides were decreased. With EFV, lipid levels increased in 
      each N[t]RTI subgroup (except triglycerides were unchanged with abacavir/3TC). 
      Fewer (P < .001) RPV-treated patients than EFV-treated patients had TC, LDL-C, 
      and triglyceride levels above National Cholesterol Education Program cutoffs. 
      More RPV- than EFV-treated patients had HDL-C values below these cutoffs (P = 
      .02). Dyslipidemia AEs were less common with RPV than with EFV. Similar 
      proportions of patients had a >/=10% decrease in limb fat (16% with RPV and 17% 
      with EFV). Limb fat was significantly (P < .001) increased to a similar extent 
      (by 12% with RPV and 11% with EFV). At week 96, patients receiving zidovudine/3TC 
      had lost limb fat, and those receiving emtricitabine/tenofovir had gained it. 
      CONCLUSIONS: Over the course of 96 weeks, RPV-based therapy was associated with 
      lower increases in lipid parameters and fewer dyslipidemia AEs than EFV-based 
      treatment. Body fat distribution changes were similar between treatments. The 
      N[t]RTI regimen affected lipid and body fat distribution changes.
CI  - (c) The Author 2014. Published by Oxford University Press on behalf of the 
      Infectious Diseases Society of America. All rights reserved. For Permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Tebas, Pablo
AU  - Tebas P
AD  - University of Pennsylvania, Philadelphia.
FAU - Sension, Michael
AU  - Sension M
AD  - Comprehensive Care Center, Fort Lauderdale, Florida.
FAU - Arribas, Jose
AU  - Arribas J
AD  - Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
FAU - Duiculescu, Dan
AU  - Duiculescu D
AD  - Titu Maiorescu University of Medicine and Dr Victor Babes Hospital for Infectious 
      and Tropical Diseases, Bucharest, Romania.
FAU - Florence, Eric
AU  - Florence E
AD  - Institute of Tropical Medicine, Antwerp.
FAU - Hung, Chien-Ching
AU  - Hung CC
AD  - National Taiwan University Hospital and National Taiwan University College of 
      Medicine, Taipei.
FAU - Wilkin, Timothy
AU  - Wilkin T
AD  - Weill Cornell Medical College, New York, New York.
FAU - Vanveggel, Simon
AU  - Vanveggel S
AD  - Janssen Infectious Diseases BVBA, Beerse, Belgium.
FAU - Stevens, Marita
AU  - Stevens M
AD  - Janssen Infectious Diseases BVBA, Beerse, Belgium.
FAU - Deckx, Henri
AU  - Deckx H
AD  - Janssen Infectious Diseases BVBA, Beerse, Belgium.
CN  - ECHO and THRIVE Study Groups
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140411
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Alkynes)
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Benzoxazines)
RN  - 0 (Cyclopropanes)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Drug Combinations)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 0 (lamivudine, zidovudine drug combination)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 4B9XT59T7S (Zidovudine)
RN  - 99YXE507IL (Tenofovir)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - FI96A8X663 (Rilpivirine)
RN  - JE6H2O27P8 (efavirenz)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alkynes
MH  - Anti-HIV Agents/*therapeutic use
MH  - Benzoxazines/*therapeutic use
MH  - Body Fat Distribution
MH  - Cyclopropanes
MH  - Dideoxynucleosides/therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - HIV Reverse Transcriptase/antagonists & inhibitors
MH  - HIV-1/*drug effects
MH  - Humans
MH  - Lamivudine/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Reverse Transcriptase Inhibitors/*therapeutic use
MH  - Rilpivirine/*therapeutic use
MH  - Tenofovir/therapeutic use
MH  - Young Adult
MH  - Zidovudine/therapeutic use
OTO - NOTNLM
OT  - dual-energy x-ray absorptiometry
OT  - efavirenz
OT  - lipids
OT  - lipodystrophy
OT  - rilpivirine
EDAT- 2014/04/15 06:00
MHDA- 2017/04/14 06:00
CRDT- 2014/04/15 06:00
PHST- 2014/04/15 06:00 [entrez]
PHST- 2014/04/15 06:00 [pubmed]
PHST- 2017/04/14 06:00 [medline]
AID - ciu234 [pii]
AID - 10.1093/cid/ciu234 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2014 Aug 1;59(3):425-34. doi: 10.1093/cid/ciu234. Epub 2014 Apr 
      11.